Home> Products> type 2 nbsp diabetes

{ "products": [ { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "683d992c87328f4e892f8716", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH 25", "description": "EMPATECH 25 is an advanced oral medication formulated with Empagliflozin 25 mg, a trusted and effective treatment for managing Type 2 Diabetes Mellitus (T2DM). It is part of a class of drugs known as SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors), designed to help lower blood sugar levels in adults when used alongside proper diet and exercise. EMPATECH 25 not only improves glycemic control but also contributes to weight management and cardiovascular health in diabetic patients.\n\nKey Ingredients\nEmpagliflozin 25 mg: A selective SGLT2 inhibitor that helps remove excess glucose from the body through urine, lowering blood sugar levels in patients with type 2 diabetes.\n\nKey Benefits\nHelps significantly reduce elevated blood glucose (HbA1c) levels in Type 2 Diabetes\n\nSupports weight loss by reducing excess sugar stored in the body\n\nAids in lowering systolic blood pressure\n\nDemonstrated cardiovascular benefits, including reduced risk of heart failure hospitalization\n\nEnhances overall glycemic control without causing hypoglycemia when used alone\n\nConvenient once-daily oral dosing\n\nHow Does It Work?\nEmpagliflozin blocks the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream.\n\nBy inhibiting this protein, the medication increases glucose excretion through urine, thereby lowering blood sugar levels.\n\nIt works independently of insulin, making it a suitable option even when insulin resistance is present.\n\nAdditionally, this mechanism reduces blood pressure and body weight, offering multiple metabolic benefits beyond blood sugar control.\n\nDirections for Use\nTake one tablet of EMPATECH 25 orally once a day, preferably at the same time each day.\n\nIt can be taken with or without food.\n\nFollow the dosage as prescribed by your healthcare provider.\n\nDo not crush, chew, or break the tablet; swallow it whole with water.\n\nMaintain regular blood sugar monitoring and adhere to a balanced diet and exercise regimen.\n\nSide Effects\nIncreased urination\n\nGenital infections (e.g., yeast infections)\n\nUrinary tract infections (UTIs)\n\nThirst and mild dehydration\n\nLow blood pressure (especially in people on diuretics)\n\nDizziness or lightheadedness\n\nPossible increase in cholesterol levels\n\nIn rare cases, ketoacidosis (seek immediate medical attention if symptoms like nausea, vomiting, or abdominal pain occur)", "price": 225.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "tablet swallow", "day preferably", "body aids", "nausea vomiting", "medical attention", "cholesterol levels", "diuretics dizziness", "crush chew", "healthcare provider", "food follow", "empatech 25 orally", "present additionally", "insulin resistance", "suitable option", "insulin making", "works independently", "sglt2 protein", "causing hypoglycemia", "reduced risk", "cardiovascular health", "weight management", "exercise empatech 25", "effective treatment", "empatech 25empatech 25", "balanced diet", "empagliflozin 25 mg", "glycemic control", "improves glycemic control", "work empagliflozin blocks", "selective sglt2 inhibitor", "alongside proper diet", "abdominal pain occur", "reabsorbing glucose back" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2130, "imageuri": "https://productimages.withfloats.com/actual/683d99313e1ed3094cddca21.png", "tileimageuri": "https://productimages.withfloats.com/tile/683d99313e1ed3094cddca21.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-02T12:29:32.123Z", "updatedon": "2025-06-02T12:31:28.199Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-25/2130", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin 25 mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 25 mg", "empagliflozin 25 mg tablet", "Empagliflozin 25 mg brands in India", "Empagliflozin 25 mg Price in India" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35e1c4d6823e26538d21d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (12.5mg), Metformin Hydrochloride (500mg)", "description": "GLIEMPAFLOZIN MET 12.5mg/500mg is a powerful combination medication formulated to manage type 2 diabetes mellitus (T2DM) effectively. It contains Empagliflozin (12.5mg) and Metformin Hydrochloride (500mg), two potent anti-diabetic agents that work synergistically to regulate blood sugar levels. This medication helps in improving glycemic control while reducing the risk of diabetes-related complications. It is prescribed as an adjunct to diet and exercise to enhance blood glucose regulation in adults with type 2 diabetes.\n\n \nKey Benefits:\n \n\n Effective Blood Sugar Control: Helps in lowering HbA1c levels, leading to better long-term glucose management.\nPromotes Weight Loss: Empagliflozin assists in weight reduction by eliminating excess glucose through urination.\nReduces Cardiovascular Risk: Beneficial for patients with heart-related complications linked to diabetes.\nImproves Insulin Sensitivity: Metformin enhances insulin action, reducing insulin resistance.\nPrevents Kidney Damage: Helps in reducing the burden on kidneys by decreasing glucose reabsorption.\nConvenient Combination Therapy: Eliminates the need for multiple medications by combining two effective drugs in one tablet.\n \nHow Does It Work?\n \n\nGLIEMPAFLOZIN MET 12.5mg/500mg works through a dual mechanism:\n\nEmpagliflozin blocks SGLT2 in the kidneys, preventing glucose reabsorption and promoting its excretion through urine. This leads to a significant reduction in blood sugar levels.\n\nMetformin lowers hepatic glucose production, decreases intestinal glucose absorption, and enhances insulin sensitivity, ensuring better blood glucose utilization by the body.\n\n \nDirections for Use:\n \n\nTake one tablet daily or as directed by your healthcare provider.\n\nSwallow the tablet whole with a glass of water. Do not crush or chew it.\n\nIt is recommended to take the medication with food to minimize gastrointestinal side effects.\n\nFollow a balanced diet and regular exercise regimen for optimal results.\n\nMonitor blood sugar levels regularly to ensure proper dosage adjustments.\n\n \nSide Effects:\n \n\nAlthough GLIEMPAFLOZIN MET 12.5mg/500mg is well tolerated, some patients may experience mild to moderate side effects, including:\n\nFrequent Urination due to glucose excretion\n\nDehydration or thirst\n\nHypoglycemia (Low Blood Sugar) when used with other anti-diabetic medications\n\nGastrointestinal Issues such as nausea, diarrhea, or stomach discomfort\n\nUrinary Tract Infections (UTIs) due to increased glucose in urine\n\nLactic Acidosis (Rare but Serious) in some cases due to Metformin", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "tablet daily", "balanced diet", "medication helps", "nausea diarrhea", "experience mild", "body directions", "significant reduction", "effective drugs", "multiple medications", "weight reduction", "work synergistically", "empagliflozin 125mg", "cases due", "diabetesrelated complications", "increased glucose", "glucose excretion dehydration", "regular exercise regimen", "metformin hydrochloride 500mg", "frequent urination due", "heartrelated complications linked", "blood glucose utilization", "eliminating excess glucose", "moderate side effects", "gliempaflozin met 125mg500mg", "healthcare provider swallow", "improving glycemic control", "potent antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2050, "imageuri": "https://productimages.withfloats.com/actual/67a35e57b167fbeb7927d316.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35e57b167fbeb7927d316.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:48:28.684Z", "updatedon": "2025-03-17T11:04:23.276Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-12-5mg-metformin-hydrochloride-500mg-/2050", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET 12.5mg/ 500mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 12.5 mg+metformin 500 mg", "empagliflozin/metformin 5 mg/1000 mg", "Empagliflozin 12.5 mg brands in India", "empagliflozin 12.5 mg+metformin 500 mg price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35d815432f8f0afe662b4", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "empagliflozin 25mg+ metformin hydrochloride (extended release) 1000 mg", "description": "GLIEMPAFLOZIN MET ER is a combination medication used to manage type 2 diabetes mellitus (T2DM) by helping control blood sugar levels effectively. It contains two powerful anti-diabetic agents, Empagliflozin and Metformin Hydrochloride (Extended Release), which work together to enhance glucose regulation and reduce the risk of diabetes-related complications. This medication is recommended for patients who require additional glycemic control beyond lifestyle changes and monotherapy treatments.\n\n \nKey Benefits\n \n\n Effective Blood Sugar Control – Helps reduce and maintain optimal blood glucose levels in type 2 diabetic patients.\nWeight Management – Empagliflozin promotes caloric loss through urinary glucose excretion, potentially aiding in weight reduction.\nReduced Risk of Cardiovascular Diseases – Beneficial for heart health, lowering the risk of cardiac complications in diabetic patients.\nInsulin Sensitivity Improvement – Metformin enhances insulin function, reducing insulin resistance.\nLower Risk of Hypoglycemia – A balanced mechanism of action ensures stable blood glucose levels without sudden drops.\nKidney Protection – Empagliflozin may help protect against diabetic nephropathy by reducing kidney stress.\nExtended-Release Formula – Ensures long-lasting blood sugar control with a once-daily dosage for improved patient compliance.\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor) – Blocks the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion through urine, thereby reducing blood sugar levels.\nMetformin Hydrochloride (Biguanide) – Reduces glucose production in the liver, enhances insulin response, and delays glucose absorption in the digestive tract.\nTogether, they provide a dual action approach for better glycemic control while minimizing side effects like hypoglycemia.\n \nDirections for Use\n \n\nDosage: Take one tablet per day, preferably with food or as directed by your healthcare provider.\nSwallow whole with a glass of water; do not crush or chew.\n Maintain a healthy diet and follow a regular exercise routine for optimal results.\nRegular monitoring of blood sugar levels is advised.\nDo not stop taking this medication without consulting your doctor.\n\n \nSide Effects:\n \n\nSome individuals may experience mild to moderate side effects, including:\n\nFrequent urination (due to glucose excretion)\nDehydration (increased fluid loss)\nNausea, vomiting, or stomach upset\nDiarrhea or constipation\nMetallic taste in the mouth\nLow blood pressure (Hypotension)\nVitamin B12 deficiency (with long-term use of Metformin)\nUrinary tract infections (UTIs) or genital infections\n Seek medical attention if you experience severe allergic reactions, extreme dizziness, or difficulty breathing.", "price": 245.0, "discountamount": 74.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "combination medication", "hypoglycemia directions", "oncedaily dosage", "difficulty breathing", "experience mild", "stop taking", "healthy diet", "chew maintain", "day preferably", "glycemic control", "digestive tract", "sglt2 protein", "diabetic nephropathy", "balanced mechanism", "cardiac complications", "diabetesrelated complications", "constipation metallic taste", "stomach upset diarrhea", "frequent urination due", "moderate side effects", "doctor side effects", "blood sugar levels", "regular exercise routine", "healthcare provider swallow", "minimizing side effects", "dual action approach", "delays glucose absorption", "improved patient compliance", "heart health lowering", "cardiovascular diseases beneficial", "enhance glucose regulation" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2049, "imageuri": "https://productimages.withfloats.com/actual/67a35d9d1b599c6f20ba1fa7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35d9d1b599c6f20ba1fa7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:45:53.712Z", "updatedon": "2025-03-27T09:45:21.627Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-metformin-hydrochloride-extended-release-1000-mg/2049", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET ER ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin + metformin brand name in india", "empagliflozin + metformin combination brand name", "empagliflozin 12.5 mg+metformin 500 mg price", "Empagliflozin and metformin hydrochloride extended-release tablets", "Empagliflozin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35c945c5e728a14d08ad8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (25mg), Linagliptin (5mg)", "description": "GLIEMPAFLOZIN LINA 25mg/5mg is a combination medication designed for individuals managing type 2 diabetes mellitus. It contains Empagliflozin (25mg) and Linagliptin (5mg), two potent anti-diabetic agents that work together to control blood sugar levels effectively. This medication is typically prescribed to patients who require dual therapy to achieve optimal glycemic control when diet and exercise alone are insufficient.\n\n \nKey Benefits :\n \n\nEffective Blood Sugar Control: Regulates blood glucose levels efficiently in patients with type 2 diabetes.\n\nWeight Management: Empagliflozin promotes weight loss by removing excess glucose from the body.\n\nHeart and Kidney Benefits: Shown to provide cardiovascular and renal protection, reducing the risk of heart failure.\n\nLower Risk of Hypoglycemia: Minimal chances of low blood sugar episodes compared to other anti-diabetic medications.\n\nConvenient Dual Therapy: Combines two complementary mechanisms for enhanced glycemic control in a single tablet.\n\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor): This component blocks Sodium-Glucose Cotransporter-2 (SGLT2) in the kidneys, preventing glucose reabsorption and facilitating its elimination through urine. This leads to a significant reduction in blood sugar levels.\n\nLinagliptin (DPP-4 Inhibitor): It inhibits Dipeptidyl Peptidase-4 (DPP-4) enzyme, which increases incretin hormone levels. This enhances insulin secretion and suppresses glucagon production, leading to better post-meal glucose control.\n\n \nDirections for Use\n \n\nTake one tablet daily, preferably at the same time each day.\n\nSwallow the tablet whole with water, with or without food.\n\nFollow the dosage regimen prescribed by your healthcare provider.\n\nRegular monitoring of blood sugar levels is recommended.\n\n \nSide Effects\n \n\nAlthough GLIEMPAFLOZIN LINA 25mg/5mg is generally well-tolerated, some patients may experience:\n\nFrequent Urination: Due to glucose excretion through urine.\n\nDehydration or Thirst: Increased urination may lead to mild dehydration.\n\nUrinary Tract Infections (UTIs): A common side effect associated with SGLT2 inhibitors.\n\nNasal Congestion or Sore Throat: Occasionally observed with DPP-4 inhibitors.\n\nGastrointestinal Discomfort: Mild nausea or diarrhea in some cases.\n\nHypotension (Low Blood Pressure): Especially in patients with pre-existing conditions.\n\n ", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "urine dehydration", "preexisting conditions", "generally welltolerated", "food follow", "day swallow", "significant reduction", "single tablet", "complementary mechanisms", "provide cardiovascular", "body heart", "linagliptin 5mg", "empagliflozin 25mg", "glucose excretion", "typically prescribed", "tablet daily preferably", "combination medication designed", "dosage regimen prescribed", "removing excess glucose", "common side effect", "thirst increased urination", "gliempaflozin lina 25mg5mg", "recommended side effects", "blood sugar levels", "enhances insulin secretion", "enhanced glycemic control", "hypoglycemia minimal chances", "renal protection reducing", "kidney benefits shown", "require dual therapy", "potent antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2048, "imageuri": "https://productimages.withfloats.com/actual/67a35cb9b07d7c125c0f536d.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35cb9b07d7c125c0f536d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:41:56.39Z", "updatedon": "2025-03-17T11:04:56.55Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-linagliptin-5mg-/2048", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN LINA 25mg/ 5mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin-linagliptin 25-5 mg price", "Empagliflozin and Linagliptin brands in India", "empagliflozin-linagliptin 10-5 mg", "Fixed dose combination of Empagliflozin and Linagliptin Tablets Price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "674b0a7ee34075b8291b14f1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride 0.5 mg, Voglibose 0.2 mg & Metformin Hydrochloride (SR) 500 mg Tablets", "description": "Diabetes management often requires a multifaceted approach to address the complexities of glucose regulation. Glimiteris Trio 0.5/0.2/500 offers a synergistic combination of three proven antidiabetic agents. This tablet not only targets fasting and postprandial blood glucose but also improves the body’s insulin utilization, ensuring better glycemic control and reducing the risk of complications associated with diabetes.\n\n \nKey Benefits:\nEffective Blood Sugar Management: Works on multiple pathways to control both fasting and postprandial blood glucose levels.\nReduces Insulin Resistance: Enhances the body's response to insulin, improving its efficacy.\nMinimizes Post-Meal Glucose Spikes: Voglibose slows carbohydrate digestion and absorption, keeping postprandial glucose in check.\nImproves Long-Term Glycemic Control: Helps in achieving and maintaining stable HbA1c levels.\nSustained Release Formula: Metformin’s SR formulation ensures prolonged action, reducing the need for frequent dosing.\nComprehensive Diabetes Management: Prevents complications like neuropathy, retinopathy, and cardiovascular issues associated with diabetes.\nHow Does It Work?\nGlimepiride: Stimulates the pancreas to release insulin, directly lowering blood glucose levels.\nVoglibose: Inhibits enzymes that break down carbohydrates into glucose, thereby delaying glucose absorption and controlling post-meal spikes.\nMetformin Hydrochloride SR: Decreases hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity, ensuring balanced glucose levels throughout the day.\nTogether, these three ingredients address the multifaceted nature of type 2 diabetes, providing a holistic solution for effective blood sugar control.\n\nDirections for Use:\nDosage: Take one tablet as prescribed by your healthcare professional, usually once or twice daily with meals.\nSwallow Whole: Do not crush or chew the tablet; it is designed for sustained release.\nTiming: Preferably consume with a meal to reduce gastrointestinal discomfort and optimize efficacy.\nFollow Medical Advice: Stick to the prescribed dosage and schedule for optimal results.\nAlways consult your doctor before starting or adjusting your dosage.\n\nSide Effects:\nWhile Glimiteris Trio 0.5/0.2/500 is generally well-tolerated, some individuals may experience side effects, including:\n\nCommon Side Effects:\n\nNausea, vomiting, or diarrhea\nStomach discomfort or flatulence\nMild hypoglycemia (low blood sugar levels)\nRare but Serious Side Effects:\n\nSevere hypoglycemia\nLactic acidosis (from Metformin)\nAllergic reactions such as rash or itching\n\n", "price": 153.0, "discountamount": 46.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "prescribed dosage", "ingredients address", "glycemic control", "targets fasting", "generally welltolerated", "glimiteris trio 0502500", "optimal results", "meals swallow", "healthcare professional", "holistic solution", "multifaceted nature", "cardiovascular issues", "neuropathy retinopathy", "insulin improving", "bodys response", "multiple pathways", "synergistic combination", "multifaceted approach", "dosage side effects", "delaying glucose absorption", "postprandial blood glucose", "metformin allergic reactions", "diarrhea stomach discomfort", "experience side effects", "reduce gastrointestinal discomfort", "work glimepiride stimulates", "proven antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2016, "imageuri": "https://productimages.withfloats.com/actual/674b0a80ec7bb8b7dcae8a8a.png", "tileimageuri": "https://productimages.withfloats.com/tile/674b0a80ec7bb8b7dcae8a8a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-11-30T12:52:14.799Z", "updatedon": "2024-11-30T12:52:14.799Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-0-5-mg-voglibose-0-2-mg-metformin-hydrochloride-sr-500-mg-tablets/2016", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS TRIO 0.5/0.2/500 ", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66d6fe913838c070275d07c9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIBENCLAMIDE IP 2.5mg, METFORMIN HYDROCHLORIDE IP 400mg", "description": "GLIBIMIDE M 2.5 /400 \nGLIBENCLAMIDE IP 2.5mg, METFORMIN HYDROCHLORIDE IP 400mg\nGLIBIMIDE M 2.5 / 400 is a potent combination medication formulated to help manage type 2 diabetes effectively. It combines the therapeutic benefits of Glibenclamide IP 2.5mg and Metformin Hydrochloride IP 400mg. This medication is designed to help control blood sugar levels, reduce the risk of complications associated with diabetes, and improve overall health. It is available at an attractive price of Rs 35.00, with a 30% discount from the MRP of Rs 50.00, inclusive of all taxes.\n\n \n\nKey Ingredients:\n \n\nGlibenclamide IP 2.5mg: Glibenclamide is a sulfonylurea class drug that stimulates the pancreas to release insulin, helping to lower blood glucose levels.\nMetformin Hydrochloride IP 400mg: Metformin belongs to the biguanide class and works by reducing glucose production in the liver and improving the body's sensitivity to insulin.\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: GLIBIMIDE M 2.5 / 400 effectively lowers high blood sugar levels in patients with type 2 diabetes, helping to prevent long-term complications.\nDual Action Formula: The combination of Glibenclamide and Metformin offers a synergistic effect, enhancing glucose control by both increasing insulin production and reducing glucose production in the liver.\nImproves Insulin Sensitivity: Metformin, one of the key ingredients, improves the body’s response to insulin, ensuring more effective management of blood sugar levels.\nReduces Risk of Diabetes Complications: By maintaining optimal blood glucose levels, GLIBIMIDE M 2.5 / 400 helps reduce the risk of complications such as neuropathy, nephropathy, and cardiovascular issues.\n \n\nHow Does It Work?\n \n\nGLIBIMIDE M 2.5 / 400 works through a two-pronged approach:\n\nGlibenclamide stimulates the pancreas to release more insulin, which helps lower blood sugar levels after meals.\nMetformin works by decreasing the amount of glucose produced by the liver and improving the sensitivity of muscle cells to insulin, allowing them to take in more glucose.\nThis dual mechanism ensures better blood sugar control throughout the day.\n\n \n\nDirections for Use:\n \n\nTake GLIBIMIDE M 2.5 / 400 exactly as prescribed by your healthcare provider. Typically, it is taken once or twice daily with meals to reduce the risk of stomach upset and to enhance its effectiveness. Swallow the tablet whole with water, without crushing or chewing it. It's important to follow your doctor's instructions closely to achieve optimal results.\n\n \n\nSide Effects:\n \n\nWhile GLIBIMIDE M 2.5 / 400 is generally well-tolerated, some patients may experience side effects, including:\n\nHypoglycemia (Low Blood Sugar): Symptoms may include dizziness, sweating, shakiness, and confusion. It is important to monitor blood sugar levels regularly.\nGastrointestinal Issues: Common side effects related to Metformin may include nausea, vomiting, diarrhea, and abdominal discomfort.\nAllergic Reactions: Rarely, some individuals may experience allergic reactions such as rash, itching, or swelling. Seek medical attention if these occur.\nWeight Gain: Glibenclamide may cause a slight increase in weight.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 50.0, "discountamount": 15.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "400 works", "Weight Gain", "GLIBIMIDE M", "30% discount", "muscle cells", "Key Benefits", "stomach upset", "overall health", "dual mechanism", "type 2 diabetes", "slight increase", "Key Ingredients", "biguanide class", "optimal results", "glucose control", "Low Blood Sugar", "attractive price", "GLIBENCLAMIDE IP", "medical attention", "insulin production", "Allergic Reactions", "synergistic effect", "glucose production", "Insulin Sensitivity", "healthcare provider", "Common side effects", "Dual Action Formula", "abdominal discomfort", "two-pronged approach", "therapeutic benefits", "effective management", "cardiovascular issues", "Diabetes Complications", "long-term complications", "Gastrointestinal Issues", "sulfonylurea class drug", "high blood sugar levels", "optimal blood glucose levels", "potent combination medication", "Effective Blood Sugar Control", "Metformin Hydrochloride IP 400mg" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1955, "imageuri": "https://productimages.withfloats.com/actual/66d6fea3e41b5cdcdef61e36.png", "tileimageuri": "https://productimages.withfloats.com/tile/66d6fea3e41b5cdcdef61e36.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-03T12:18:25.8Z", "updatedon": "2024-09-03T12:18:25.8Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glibenclamide-ip-2-5mg-metformin-hydrochloride-ip-400mg/1955", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIBIMIDE M 2.5 /400", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }